Clinical trialPhase 1 / Phase 2Completed
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects With Advanced Refractory Cancers
- Outcome
- Results posted; no analysis attached
- Phase
- Phase 1 / Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- 9 February 2017
- Ended
- 22 February 2023
- Enrollment
- 111 participants
- Sites
- 8
- Primary outcomes
- Rate and Severity of Treatment-emergent Adverse Events ≥ Grade 3 Attributed to Study Drug Using the NCI Common Terminology Criteria for Adverse Events (CTCAE v.4.03) (Scale 1 to 5)
- Sponsor type
- Industry
- Results posted
- 13 August 2024
- Last update
- 27 February 2025
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; no analysis attachedAs posted on ClinicalTrials.gov ↗, registry record of 27 February 2025
- Primary outcome
- Rate and Severity of Treatment-emergent Adverse Events ≥ Grade 3 Attributed to Study Drug Using the NCI Common Terminology Criteria for Adverse Events (CTCAE v.4.03) (Scale 1 to 5)Monotherapy: Cohort A1: 0 of 6Monotherapy: Cohort B1: 0 of 4Monotherapy: Cohort EA: 1 of 4Monotherapy: Cohort EC: 2 of 21Monotherapy: Cohort EC-2: 4 of 20Monotherapy: Cohort EC3: 0 of 9INT 230-6 Combined With Pembrolizumab (Cohort DEC): 1 of 6INT 230-6 Combined With Pembrolizumab (Cohort DEC2): 6 of 22Values: ParticipantsTime frame: Up to 5 yearsNo analysis posted for this outcome (outcome 1)
- Participants
- Monotherapy: Cohort A1: 6 started, 1 completedMonotherapy: Cohort B1: 4 started, 1 completedMonotherapy: Cohort EA: 4 started, 1 completedMonotherapy: Cohort EC: 21 started, 9 completedMonotherapy: Cohort EC-2: 20 started, 9 completedMonotherapy: Cohort EC3: 9 started, 3 completedINT 230-6 Combined With Pembrolizumab (Cohort DEC): 6 started, 3 completedINT 230-6 Combined With Pembrolizumab (Cohort DEC2): 22 started, 5 completedINT 230-6 Combined With Ipilimumab (Cohort FEC): 18 started, 13 completed
- Serious adverse events
- Monotherapy: (Cohort A1): 0 of 6Monotherapy: (Cohort B1): 0 of 4Monotherapy: (Cohort E-A): 0 of 4Monotherapy: (Cohort E-C): 1 of 21Monotherapy: (Cohort EC-2): 1 of 20Monotherapy: (Cohort EC3): 1 of 9INT230-6 Combined With Pembrolizumab (Cohorts DEC): 2 of 8INT230-6 Combined With Pembrolizumab (Cohorts DEC2): 2 of 22INT 230-6 Combined With Ipilimumab (Cohort FEC): 1 of 18Participants with at least one serious adverse event, of those at risk, as posted
4 secondary outcomes
- DCR · Preliminary Efficacy: Assess the Preliminary Efficacy of INT230-6 by Measuring the …
- Monotherapy (Cohorts A1/B1/EA/EC/EC2/EC… 83.3, n=48; Monotherapy (Cohorts A1/B1/EA/EC/EC2/EC… 50.0, n=16; INT230-6 Combined With Pembrolizumab (C… 64.3, n=28; INT 230-6 Combined With Ipilimumab (Coh… 83.3, n=18 [percentage (DCR)]
- Determine Pharmacokinetic Parameter Peak Plasma (Cmax in ng/mL) of Each of the 3 Main Com…
- Mean INT230-6 Dose Category: 2mL: Pharmacokinetic (PK) Analysis Populatio… 34.27 (25.51), n=10; Pharmacokinetic Analysis Population (Co… 74.93 (70.8), n=8; Pharmacokinetic Analysis Population (Co… 1.35 (1.7), n=3 [mean ng/mL, Standard Deviation] (first of 7 rows)
- Determine Key Pharmacokinetic Parameter, Area Under the Curve (AUC) (ng/mL) of Each of th…
- Mean INT230-6 Dose Category: 2mL Time point: 0 Ho…: Pharmacokinetic (PK) Analysis Populatio… 6.38 (20.18), n=10; Pharmacokinetic Analysis Population (Co… 0 (0), n=10; Pharmacokinetic Analysis Population (Co… .33 (1.05), n=10 [mean ng/mL, Standard Deviation] (first of 35 rows)
- Key Pharmacokinetic Parameters, Half Live (Hours) of Each of the 3 Main Components of INT…
- Mean INT230-6 Dose Category: 2mL: Pharmacokinetic (PK) Analysis Populatio… 77.98 (34.92), n=4 [mean Hours, Standard Deviation] (first of 7 rows)
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This study evaluated the intratumoral administration of escalating doses of a novel, experimental drug, INT230-6. The study was conducted in patients with several types of refractory cancers including those at the surface of the skin (breast, squamous cell, head and neck) and tumors within the body such (pancreatic, colon, liver, lung, etc.). Sponsor also tested INT230-6 in combination with anti-PD-1 and anti-CTLA-4 antibodies.
Detailed description public domain (ClinicalTrials.gov)
INT230-6 is comprised of 3 agents in a fixed ratio - a cell permeation enhancer and two, potent anti-cancer payloads (cisplatin and vinblastine sulfate). The penetration enhancer facilitates dispersion of the two drugs throughout injected tumors and enables increased diffusion into cancer cells. Nonclinical safety studies showed no findings following drug injection into healthy tissues. Historically physicians administer the two active drugs comprising INT230-6 by intravenous (IV) infusion to achieve a systemic blood level at the limit of tolerability. The objective is destroy both visible tumors and unseen circulating cancer cells (micro-metastases). Unfortunately, dosing drugs IV delivers only a small amount with a low concentration at the tumor site. This approach especially for late stage cancers is not highly effective and often quite toxic to the patient. Attempts at direct intratumoral injection with chemotherapeutic agents have not shown the ability to treat the injected tumor, non-injected tumors or micro-metastases. This lack of efficacy for local administration is due possibly to poor dispersion and a lack of cell uptake of the agents. Due to the use of the novel cell penetration enhancing agent INT230-6 treatment demonstrated strong efficacy in animals having large tumors. The Sponsor's in vivo, non-clinical data shows that INT230-6 thoroughly saturates and kills injected tumors. In addition, the drug induces an adaptive (T-cell mediated) immune response that attacks not only the injected tumor, but non-injected tumors and unseen micro-metastases. Cured animals become permanently immunized against the type of cancer that INT230-6 eliminates. Clinical trial IT-01 sought to determine the safety and potential efficacy of dosing INT230-6 directly into several different types of cancers. In addition, animal studies showed a strong synergy of INT230-6 with immune modulation agents. Thus, as part of study IT-01 the Sponsor seeks to understand the safety and efficacy of INT230-6 when administered in combination with immuno-therapeutic agents such as antibodies that target Programmed Cell Death (PD-1 or anti-PD-1) and Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4 or anti-CTLA-4) receptors. This study sought to understand whether tumor regression can be achieved, and patient outcomes improved.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Rate and Severity of Treatment-emergent Adverse Events ≥ Grade 3 Attributed to Study Drug Using the NCI Common Terminology Criteria for Adverse Events (CTCAE v.4.03) (Scale 1 to 5) [Up to 5 years]. Count Of Participants, Participants. Monotherapy: Cohort A1 (n=6): 0; Monotherapy: Cohort B1 (n=4): 0; Monotherapy: Cohort EA (n=4): 1; Monotherapy: Cohort EC (n=21): 2; Monotherapy: Cohort EC-2 (n=20): 4; Monotherapy: Cohort EC3 (n=9): 0; INT 230-6 Combined With Pembrolizumab (Cohort DEC) (n=6): 1; INT 230-6 Combined With Pembrolizumab (Cohort DEC2) (n=22): 6; INT 230-6 Combined With Ipilimumab (Cohort FEC) (n=18): 2.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Preliminary Efficacy: Assess the Preliminary Efficacy of INT230-6 by Measuring the Disease Control Rate (DCR) Based on the Response Evaluation Criteria in Solid Tumors (RECIST) and Immune RECIST (iRECIST) Criteria, [Up to 5 years]. Number, percentage (DCR). Monotherapy (Cohorts A1/B1/EA/EC/EC2/EC3) [Dosed >/= 40%TTB] (n=48): 83.3; Monotherapy (Cohorts A1/B1/EA/EC/EC2/EC3) [Dosed <40%TTB] (n=16): 50.0; INT230-6 Combined With Pembrolizumab (Cohorts DEC/DEC2) (n=28): 64.3; INT 230-6 Combined With Ipilimumab (Cohort FEC) (n=18): 83.3.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Determine Pharmacokinetic Parameter Peak Plasma (Cmax in ng/mL) of Each of the 3 Main Components of INT230-6. [T = 1 hour after first dose]. Mean, ng/mL (Standard Deviation). Mean INT230-6 Dose Category: 2mL: Pharmacokinetic (PK) Analysis Population (Component 1: Cisplatin) (n=87): 34.27 (25.51); Pharmacokinetic Analysis Population (Component 2: SHAO) (n=85): 74.93 (70.8); Pharmacokinetic Analysis Population (Component 3: Vinblastine) (n=79): 1.35 (1.7). Mean INT230-6 Dose Category: 5mL: Pharmacokinetic (PK) Analysis Population (Component 1: Cisplatin) (n=87): 77.81 (38.16); Pharmacokinetic Analysis Population (Component 2: SHAO) (n=85): 113.7 (83.2); Pharmacokinetic Analysis Population (Component 3: Vinblastine) (n=79): .73 (.77). Mean INT230-6 Dose Category: 10mL: Pharmacokinetic (PK) Analysis Population (Component 1: Cisplatin) (n=87): 153.8 (65.75); Pharmacokinetic Analysis Population (Component 2: SHAO) (n=85): 300.6 (172.6); Pharmacokinetic Analysis Population (Component 3: Vinblastine) (n=79): .75 (.33). Mean INT230-6 Dose Category: 17mL: Pharmacokinetic (PK) Analysis Population (Component 1: Cisplatin) (n=87): 245.8 (119.3); Pharmacokinetic Analysis Population (Component 2: SHAO) (n=85): 426.8 (306.6); Pharmacokinetic Analysis Population (Component 3: Vinblastine) (n=79): 1.24 (.67). Mean INT230-6 Dose Category: 30mL: Pharmacokinetic (PK) Analysis Population (Component 1: Cisplatin) (n=87): 456.5 (195.0); Pharmacokinetic Analysis Population (Component 2: SHAO) (n=85): 911.6 (790.1); Pharmacokinetic Analysis Population (Component 3: Vinblastine) (n=79): 3.16 (1.99). Mean INT230-6 Dose Category: 68mL: Pharmacokinetic (PK) Analysis Population (Component 1: Cisplatin) (n=87): 952.2 (503.8); Pharmacokinetic Analysis Population (Component 2: SHAO) (n=85): 1446 (1245); Pharmacokinetic Analysis Population (Component 3: Vinblastine) (n=79): 5.63 (2.33). Mean INT230-6 Dose Category: 118mL: Pharmacokinetic (PK) Analysis Population (Component 1: Cisplatin) (n=87): 1673 (1276); Pharmacokinetic Analysis Population (Component 2: SHAO) (n=85): 2720 (1848); Pharmacokinetic Analysis Population (Component 3: Vinblastine) (n=79): 9.52 (4.52).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Determine Key Pharmacokinetic Parameter, Area Under the Curve (AUC) (ng/mL) of Each of the 3 Main Components of INT230-6. [T= 0, 1, 3, 6, 24 Hours after dosing]. Mean, ng/mL (Standard Deviation). Mean INT230-6 Dose Category: 2mL Time point: 0 Hours: Pharmacokinetic (PK) Analysis Population (Component 1: Cisplatin) (n=87): 6.38 (20.18); Pharmacokinetic Analysis Population (Component 2: SHAO) (n=85): 0 (0); Pharmacokinetic Analysis Population (Component 3: Vinblastine) (n=79): .33 (1.05). Mean INT230-6 Dose Category: 2mL Time point: 1 Hour(s): Pharmacokinetic (PK) Analysis Population (Component 1: Cisplatin) (n=87): 33.78 (24.92); Pharmacokinetic Analysis Population (Component 2: SHAO) (n=85): 59.94 (69.95); Pharmacokinetic Analysis Population (Component 3: Vinblastine) (n=79): .08 (.16). Mean INT230-6 Dose Category: 2mL Timepoint: 3 Hours: Pharmacokinetic (PK) Analysis Population (Component 1: Cisplatin) (n=87): 28.09 (23.16); Pharmacokinetic Analysis Population (Component 2: SHAO) (n=85): 3.33 (6.99); Pharmacokinetic Analysis Population (Component 3: Vinblastine) (n=79): .04 (.12). Mean INT230-6 Dose Category: 2mL Timepoint: 6 Hours: Pharmacokinetic (PK) Analysis Population (Component 1: Cisplatin) (n=87): 25.35 (20.35); Pharmacokinetic Analysis Population (Component 2: SHAO) (n=85): 0 (0); Pharmacokinetic Analysis Population (Component 3: Vinblastine) (n=79): 0 (0). Mean INT230-6 Dose Category: 2mL Timepoint: 24 Hours: Pharmacokinetic (PK) Analysis Population (Component 1: Cisplatin) (n=87): 20.74 (17.22); Pharmacokinetic Analysis Population (Component 2: SHAO) (n=85): 0 (0); Pharmacokinetic Analysis Population (Component 3: Vinblastine) (n=79): 0 (0). Mean INT230-6 Dose Category: 5mL Timepoint: 0 Hours: Pharmacokinetic (PK) Analysis Population (Component 1: Cisplatin) (n=87): 1.56 (4.67); Pharmacokinetic Analysis Population (Component 2: SHAO) (n=85): 0 (0); Pharmacokinetic Analysis Population (Component 3: Vinblastine) (n=79): 0 (0). Mean INT230-6 Dose Category: 5mL Timepoint: 1 Hour(s): Pharmacokinetic (PK) Analysis Population (Component 1: Cisplatin) (n=87): 77.81 (38.16); Pharmacokinetic Analysis Population (Component 2: SHAO) (n=85): 113.74 (83.23); Pharmacokinetic Analysis Population (Component 3: Vinblastine) (n=79): .65 (.76). Mean INT230-6 Dose Category: 5mL Timepoint: 3 Hours: Pharmacokinetic (PK) Analysis Population (Component 1: Cisplatin) (n=87): 58.50 (30.57); Pharmacokinetic Analysis Population (Component 2: SHAO) (n=85): 11.43 (15.52); Pharmacokinetic Analysis Population (Component 3: Vinblastine) (n=79): .16 (.16). Mean INT230-6 Dose Category: 5mL Timepoint: 6 Hours: Pharmacokinetic (PK) Analysis Population (Component 1: Cisplatin) (n=87): 59.04 (32.03); Pharmacokinetic Analysis Population (Component 2: SHAO) (n=85): 2.18 (6.15); Pharmacokinetic Analysis Population (Component 3: Vinblastine) (n=79): 0 (0). Mean INT230-6 Dose Category: 5mL Timepoint: 24 Hours: Pharmacokinetic (PK) Analysis Population (Component 1: Cisplatin) (n=
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Key Pharmacokinetic Parameters, Half Live (Hours) of Each of the 3 Main Components of INT230-6. [T= 0, 1, 3, 6, 24 hours]. Mean, Hours (Standard Deviation). Mean INT230-6 Dose Category: 2mL: Pharmacokinetic (PK) Analysis Population (Component 1: Cisplatin) (n=26): 77.98 (34.92). Mean INT230-6 Dose Category: 5mL: Pharmacokinetic (PK) Analysis Population (Component 1: Cisplatin) (n=26): 130.4 (129.8). Mean INT230-6 Dose Category: 10mL: Pharmacokinetic (PK) Analysis Population (Component 1: Cisplatin) (n=26): 106.3 (53.58); Pharmacokinetic Analysis Population (Component 3: Vinblastine) (n=28): 18.82. Mean INT230-6 Dose Category: 17mL: Pharmacokinetic (PK) Analysis Population (Component 1: Cisplatin) (n=26): 78.73 (66.36); Pharmacokinetic Analysis Population (Component 2: SHAO) (n=6): 7.33; Pharmacokinetic Analysis Population (Component 3: Vinblastine) (n=28): 20.11 (7.45). Mean INT230-6 Dose Category: 30mL: Pharmacokinetic (PK) Analysis Population (Component 1: Cisplatin) (n=26): 64.77 (15.18); Pharmacokinetic Analysis Population (Component 2: SHAO) (n=6): 7.48; Pharmacokinetic Analysis Population (Component 3: Vinblastine) (n=28): 15.35 (4.38). Mean INT230-6 Dose Category: 68mL: Pharmacokinetic (PK) Analysis Population (Component 1: Cisplatin) (n=26): 129.4 (125.5); Pharmacokinetic Analysis Population (Component 2: SHAO) (n=6): 3.91 (2.6); Pharmacokinetic Analysis Population (Component 3: Vinblastine) (n=28): 14.06 (3.7). Mean INT230-6 Dose Category: 118mL: Pharmacokinetic Analysis Population (Component 2: SHAO) (n=6): 6.18; Pharmacokinetic Analysis Population (Component 3: Vinblastine) (n=28): 24.48 (4.76).